Biosimilars to Roche’s Actemra/RoActemra (tocilizumab) in the US and Europe have not hit as hard as expected, the Swiss originator has outlined.
Fresenius Kabi recently stepped up marketing of its Tyenne (tocilizumab-aazg) rival to Actemra in the US, introducing the country’s first subcutaneous tocilizumab biosimilar alongside the existing intravenous version that...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?